And DHA content material of human erythrocytes. Lipids. 2005; 40:34347. [PubMed: 16028715] 20. Klein, J.; Moeschberger, M. Survival Evaluation: Strategies for Censored and Truncated Data. two. Springer-Verlag; 2003. 21. Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement in the American Heart Association. Circulation. 2009; 119:2408416. [PubMed: 19364974] 22. Pencina MJ, D’Agostino RB. General C as a measure of discrimination in survival evaluation: model precise population worth and confidence interval estimation. Stat Med. 2004; 23:2109123. [PubMed: 15211606] 23. Antolini L, Nam BH, D’Agostino RB. Inference on correlated discrimination measures in survival analysis: a nonparametric approach. Commun Stat Theory Meth. 2004; 33:2117135. 24. Pencina MJ, D’Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011; 30:111. [PubMed: 21204120] 25. D’Agostino, RB.; Nam, BH. Evaluation in the performance of survival analysis models: discrimination and calibration measures. In: Balakrishnan, N.; Rao, CR., editors. Handbook of Statistics. Vol. 23. London: Elsevier; 2004. 26. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem. 2008; 54:173. [PubMed: 18024533] 27. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary danger prediction employing C-reactive protein as well as other novel danger markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006; 166:1368373. [PubMed: 16832001] 28. Lorgis L, Cottin Y, Danchin N, et al. Impact of obesity on the prognostic value on the N-terminal pro-B-type natriuretic peptide (NT-proBNP) in individuals with acute myocardial infarction. Heart. 2011; 97:55156. [PubMed: 21343169]NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptInt J Cardiol. Author manuscript; out there in PMC 2014 September 20.Harris et al.Page29. Narayan H, Dhillon OS, Quinn P, et al. C-Terminal Provasopressin (Copeptin) as Prognostic Marker right after Acute Non ST Elevation Myocardial Infarction – Leicester Acute Myocardial Infarction Peptide II (LAMP II) study. Clin Sci (Lond). 2011 30. Timoteo AT, Toste A, Ramos R, et al. Does admission NT-proBNP raise the prognostic accuracy of GRACE danger score within the prediction of short-term mortality following acute coronary syndromes Acute Card Care. 2009; 11:23642.Eriocitrin Epigenetics [PubMed: 19742352] 31.N-Methylmesoporphyrin IX Formula Meune C, Drexler B, Haaf P, et al.PMID:24455443 The GRACE score’s performance in predicting inhospital and 1-year outcome inside the era of high-sensitivity cardiac troponin assays and B-type natriuretic peptide. Heart. 2011 32. Lee SH, Shin MJ, Kim JS, et al. Blood eicosapentaenoic acid and docosahexaenoic acid as predictors of all-cause mortality in individuals with acute myocardial infarction–data from Infarction Prognosis Study (IPS) Registry. Circ J. 2009; 73:2250257. [PubMed: 19789416] 33. Ueeda M, Doumei T, Takaya Y, et al. Association of serum levels of arachidonic acid and eicosapentaenoic acid with prevalence of key adverse cardiac events just after acute myocardial infarction. Heart Vessels. 2011; 26:14552. [PubMed: 20963593] 34. Harris WS, von Schacky C. The Omega-3 Index: a brand new danger element for death from coronary heart disease Prev Med. 2004; 39:21220. [PubMed: 15208005] 35. Block RC, Harris WS, Reid KJ, Sands SA, Spertus JA. EPA and DHA in Blood Cell Membranes from Acute Cor.
